The multifaceted mechanism of Leptin signaling within tumor microenvironment in driving breast cancer growth and progression

Sebastiano Andò1*, Ines Barone1, Cinzia Giordano2, Daniela Bonfiglio1 and Stefania Catalano1

1 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy
2 Centro Sanitario, University of Calabria, Rende, Italy

INTRODUCTION

Breast cancer, a complex and heterogeneous disease, is one of the most common human malignancies in women worldwide. Breast cancer development and progression depend on both the accumulation of various genetic alterations in the epithelial cells of the mammary gland, and the reciprocal interaction between tumor cell itself and its surrounding microenvironment (stroma). The stroma of the breast is composed of the extracellular matrix components (ECM) as well as several cellular types such as endothelial cells, pericytes, immune and inflammatory cells, adipocytes, and fibroblasts [termed cancer-associated fibroblasts (CAFs)] (1). In breast tumors, 80% of CAFs are in active form (2), and secrete high levels of various growth factors, cytokines, chemokines, and ECM degrading proteases (3) that by different mechanisms promote breast tumor onset and progression. In this regard, we recently identified leptin as a main regulator in the crosstalk between breast cancer cells and CAFs, adding, for the first time, leptin to the list of growth factors, cytokines, chemokines, and ECM degrading proteases that by different mechanisms promote breast tumor onset and progression (4).

Leptin, whose synthesis and plasma levels increase proportionally to total adipose-tissue mass (5, 6), is a pleiotropic molecule that regulates food intake, inflammation, immunity, cell differentiation, and proliferation of different cell types including cells of the breast (7). The activities of leptin are mediated through the transmembrane leptin receptor (ObR) encoded by db gene, a member of the class I cytokine receptor family that includes six isoforms different in the length of their intracellular tails (8). Leptin binding to ObR induces activation of multiple intracellular signaling pathways such as Janus kinase 2-signal transducer and activator of transcription 3 (JAK2-STAT3), mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) pathways (9, 10) involved in different cellular activities. In the last decades, a plethora of data, strongly support the idea that leptin activity is correlated with breast cancer occurrence. Indeed, both leptin and its receptor are overexpressed in breast cancer, especially in higher grade tumors and are associated with distant metastasis (11, 12). Particularly, it has been extensively demonstrated using both in vitro and in vivo experimental models, that this adipokine modulates many aspects of breast cancer biology: e.g., increases cell proliferation and transformation, induces the expression of several cell cycle modulators, exerts anti-apoptotic effects, reduces efficacy of breast cancer treatment, influences cancer initiation processes (Table 1). Moreover, we and other authors have demonstrated that leptin can exert its activity also interacting with different signaling molecules.

In this review, we will focus on the role of leptin in breast cancer highlighting the following topics: (1) leptin as an amplifier of estrogen signaling in tumor epithelial cells contributing to the promotion of carcinogenesis; (2) leptin as a crucial player in tumor epithelial cells enhancing breast cancer cell motility and invasiveness. In addition, it has been reported that leptin may induce breast cancer to undergo a transition from epithelial to spindle-like mesenchymal morphology, activating the signaling pathways devoted to the EMT. Thus, it emerges how leptin may play a crucial role in mediating malignant cell and tumor microenvironment interactions. Here, we present an overview of the role of leptin in breast cancer, covering the following topics: (1) leptin as an amplifier of estrogen signaling in tumor epithelial cells contributing to the promotion of carcinogenesis; (2) leptin as a crucial player in mediating tumor-stroma interaction and influencing EMT-linked mechanisms, that may sustain breast cancer growth and progression; (3) leptin and leptin receptor targeting as novel therapeutic strategies for breast cancer treatment.

Keywords: breast cancer, leptin-signaling pathway, estrogen receptor, tumor microenvironment, EMT, stem cells
Table 1 | Role of leptin in breast cancer growth and progression: in vitro and in vivo studies.

| Experimental models | Findings | References |
|---------------------|----------|------------|
| **IN VITRO**        |          |            |
| MCF-7               | Increased cell proliferation | (4, 13–24) |
| T47D                |          |            |
| ZR75-1              |          |            |
| MDA-B-361           |          |            |
| SKBR3               |          |            |
| MDA-MB-231          |          |            |
| MCF-7               | Increased cell transformation | (4, 17, 25) |
| T47D                |          |            |
| SKBR3               |          |            |
| MCF-7               | Up-regulation of cdk2, cyclin D1, E-cadherin, hyperphosphorylation of pRb, activation of estrogen receptor, induced expression of c-myc | (16, 17, 19, 21, 24, 26–28) |
| ZR75-1              |          |            |
| MCF-7               | Anti-apoptotic effect | (27, 29, 30) |
| ZR75-1              |          |            |
| MCF-7               | Reduced efficacy of breast cancer treatment | (16, 25) |
| **IN VIVO**         |          |            |
| Obese Zucker rats   | Small percentage of carcinoma developed in obese compared with lean rats | (31) |
| MMTV/TGF-α          | No transgene-induced mammary tumors development | (32) |
| Lepob/ob            |          |            |
| MMTV/TGF-α          | No transgene-induced mammary tumors development | (33) |
| Lepob/ob            |          |            |
| MMTV/PyMT-α         | Reduced mammary tumor growth and progression | (34) |
| db/dbNSE/NSE        | Enhanced mitochondrial β-oxidation | |
| MMTV/Wnt1 tumors    | Suppressed mammary tumor growth and tumor-initiating cell survival | (35) |
| transplanted in Lepob/ob |          |            |

mediating tumor-stroma interaction and influencing EMT-linked mechanisms, that may sustain breast cancer growth and progression; (3) leptin and leptin receptor targeting as novel therapeutic strategies for breast cancer treatment.

**FUNCTIONAL CROSS-TALK BETWEEN LEPTIN AND ESTROGENS**

In addition to leptin, adipose tissue is a source of estrogens produced from androstenedione via aromatase conversion in postmenopausal women. Interestingly, several investigators have reported evidences that a functional cross-talk occurs between leptin and estrogen signaling network further contributes to breast carcinogenesis. Indeed, estrogen receptor (ER) α and ObRs are coexpressed in malignant mammary tissue and breast cancer cell lines (15, 17, 18) and it has been shown a positive association between serum leptin levels and elevated values of estrogen and progesterone receptor in patients with breast cancer (36, 37).

Similarly, in human primary breast cancers, leptin receptor expression is positively correlated with tumor size and ER expression (38). Moreover, it has been reported that estradiol administration increases leptin mRNA expression in adipose tissue (39) and induces an enhanced leptin and ObR expression in MCF-7 breast cancer cells (40).

On the other hand, leptin is a potent modulator of the estrogen signaling pathway. Specifically, we reported that leptin is able to activate ERα transcriptionally through MAPK pathway in breast cancer cells in the absence of its natural ligand, reproducing the classic features of ERα transactivation, such as nuclear localization, down-regulation of its mRNA and protein levels, and up-regulation of classic estrogen-dependent genes (26). Recently, we have also demonstrated that a lysine to arginine mutation at residue 303 (K303R) within the hinge domain of ER may potentiate ERα’s role as an effector of leptin intracellular signal transduction, which may enhance cell proliferation, migration and invasiveness, contributing to the more aggressive phenotype of K303R-associated breast cancers (4). Moreover, leptin-induced activation of ERK and STAT3 has been correlated with an increased expression of ERα in breast cancer cells (41) and in breast tumors of nude-mouse xenograft model (42). This evidence is also confirmed by analysis of 33 patients with breast cancer at different stages of disease, demonstrating a significant association between the expression of leptin receptor and ERα (41).

Leptin also interferes with the estrogen antagonists ICI 182,780 and tamoxifen used in the treatment of ERα-positive tumors (16, 43).

Further evidence for the involvement of leptin in the paracrine stimulation of estrogen-responsive tissues is provided by its capacity to induce CYP19A1 synthesis in stromal cells isolated from the subcutaneous fat and breast adipose tissue of premenopausal women (44). In addition, Brown and colleagues have demonstrated that leptin stimulates aromatase expression in human breast adipose stromal cells through the regulation of LKB1/AMPK (AMP-activated protein kinase) pathway (45). Notably, they show that leptin downregulates LKB1 expression, accompanied by a decrease in AMPK phosphorylation, increased nuclear translocation of CRTC2 (CREB-regulated transcription coactivator 2), and a resulting increase in aromatase expression. Moreover, it has been reported that leptin enhances aromatase mRNA expression, protein content and its enzymatic activity in breast cancer cells, thereby promoting estradiol synthesis (13). This is mediated by AP1 (transcription activator protein 1) in ERK- and STAT3-dependent manner, since the presence of a MAPK inhibitor, ERK2- or STAT3-dominant negative constructs markedly attenuated the stimulatory effects of leptin on aromatase.

The enhanced local estrogen production induced by leptin could potentially also shape the breast cancer microenvironment. For example, local estrogens up-regulate TNF (tumor necrosis factor) receptor I expression in adipose-tissue fibroblast in an
autocrine manner. Breast cancer epithelial cells produce large amounts of TNF, which through binding to TNF receptor I inhibits the differentiation of fibroblasts and preadipocytes into mature adipocytes, providing a molecular basis for the desmoplastic reaction commonly seen in breast cancer (46).

Overall, these studies indicate a biologically relevant cooperation between leptin and estrogen signaling pathways that might sustain the growth of estrogen-dependent breast cancer cells.

**Molecular Connection Between Leptin and EMT**

In patients with breast cancer, metastasis rather than the primary tumor is the main cause of death. Epithelial-to-mesenchymal transition (EMT), a normal physiological process for embryonic development and wound healing, is thought to be involved in cancer progression and metastasis. Indeed, EMT represents a critical step in which a normal polarized epithelial cell undergoes several biochemical changes to acquire a mesenchymal cell phenotype, such as acquisition of migratory and invasive capabilities and the loss of cell–cell adhesion and cell polarity, resulting in tumor aggressiveness, recurrence, and overall poor prognosis. Recently, it has been found that CAFs and fibroblasts from breast reduction specimens are able to induce EMT in breast cancer cell lines (47–49). The role played by CAFs in the development and progression of breast cancer relies on their ability to produce stromal ECM (extracellular matrix) proteins and secrete many growth factors and hormones, including insulin like growth factor (IGF)-1, IGF-II, epidermal growth factor (EGF), transforming growth factor (TGF)-α, TGF-β (3). For instance, stromal fibroblasts isolated from invasive breast cancer tissues promote aggressive phenotypes of breast cancer cells through EMT induced by paracrine TGF-β1 (50). Recently, we showed for the first time ObR RNA expression and leptin secretion in CAFs, proposing a novel integral role for leptin in mediating the bidirectional crosstalk between breast cancer cells and CAFs driving tumor growth and invasion (4). In parallel, it has been shown that leptin and its receptor initiate EMT via PI3K/Akt signaling pathway and β-catenin stabilization and nuclear translation in breast cancer cells (51). The investigators observed in leptin-treated ERα-positive MCF-7 breast cancer cells as compared with untreated cells morphological phenotypic changes, including acquisition of fibroblast-like appearance, increased formation of pseudopodia from the cell membrane, reorganization of actin, and formation of stress fibers throughout cytoplasm. Such phenotypic differences were also reproduced upon leptin treatment in ERα-negative MDA-MB-231 and in MDA-MB-468 breast cancer cells. Exposure of cells to leptin stimulation resulted in loss of expression of E-cadherin and up-regulation of mesenchymal markers, which include N-cadherin, fibronectin, and vimentin. Expression of EMT inducers such as Snail, Slug, Zeb1, and Twist has also been found. The key mechanism underlying this important function of leptin involves a previously unrecognized interactions between leptin, metastasis-associated protein 1 (MTA1) and Wnt/β-catenin pathways.

Over the last decade, it is emerged that EMT is involved in the generation and function of breast cancer stem cells (BCSCs), a population of highly tumorigenic cells characterized by the expression of molecular markers (phenotype CD44+/CD24−/ALDH1+) that, in favorable microenvironments, self-renew, proliferate, and can differentiate to cells that include the bulk of the tumor mass. These cells appear to promote angiogenesis and escape immune surveillance, and chemo- and radio-therapy (52). Leptin has been reported to regulate and activate several signaling pathways and oncogenes, such as HER2, and AKT as well as transcription factors, such as STAT3 and NF-κB, which are critically implicated in BCSCs (53, 54). In addition, leptin also activates the Notch signaling pathway (55, 56) that is an important stem-cell signaling network. Interestingly, it has been found that leptin induces the expression of CD44 and ALDH1 in several cancer cell lines (53). Zheng et al. have reported a decreased tumor outgrowth and a functional depletion of BCSCs in obese leptin-deficient mice transplanted with murine mammary tumor virus (MMTV)-Wnt1 tumor cells, showing that leptin signaling has an important role in tumor cell growth and stem-cell survival (35). Another study has also demonstrated that expression of Ob-R is a characteristic feature of CSCs, that display sensitized responses to leptin, such as STAT3 phosphorylation and activation along with Oct4 and Sox2 overexpression, thereby creating a self-reinforcing signaling network (57).

Given all the potential roles of leptin in the multistep processes of breast cancer progression, involving tumor initiation, primary tumor growth, invasion and metastasis, the leptin-signaling network is emerging as a novel therapeutic target for patients with breast cancers.

**Leptin as a Potential Target of the Novel Therapeutic Strategies for Breast Cancer Treatment**

Several therapeutic approaches that could interfere with the actions of leptin and thereby prevent or delay leptin-related disease have been proposed (59).

**Soluble Leptin Receptors**

Recombinant leptin-binding domains have been indicated as a treatment to block free leptin but they do not completely neutralize leptin activity due to a lower affinity for leptin compared to the intact soluble leptin receptor. (60, 61). However, several investigators have synthesized receptor-binding fragments able to inhibit leptin-induced proliferation and oncogenic signaling in both ER-positive and -negative breast cancer cells (62–64).

**Peptide-Based Leptin Antagonists**

An altered form of human leptin containing the mutation Arg128Gln was the first leptin antagonist synthesized. This mutant, tested in BAF/3 cells (an immortalized murine bone marrow-derived pro-B-cell line) stably transfected with the long form of human leptin receptor, exhibited binding properties similar to wild-type leptin, although it demonstrated reduced biological activity and weak antagonist properties when tested in cell proliferation assays (65). Another study has demonstrated that high doses of a short peptide sequences corresponding to amino acids 70–95 of human leptin is able to reverse leptin activity in vitro and in vivo (66–68). Moreover, Gertler et al. have demonstrated that mutations in sequence 39-42 (LDFI) of leptin lead to leptin
muteins that still bind the receptor, but do not activate it (69, 70). Conversion of these amino acids to alanine resulted in the creation of leptin antagonists, being able to block endogenous leptin action in intact animals. Subsequent studies have (71–73) discovered another residue, Asp23, whose mutagenesis is associated with a dramatic increase in leptin-binding affinity. The simultaneous mutation of Asp23 with leucine and LDF with alanine, made it possible to synthesize the mutein D23L/L39A/D40A/F41A having a binding affinity receptor 60 times greater and antagonistic activity 14 times greater, in vitro, compared to the simple mutation LDF. Recently, we have synthesized a small peptide based on the wild-type sequence of leptin-binding site I, and demonstrated its efficacy in antagonizing leptin activity in breast cancer cell lines and in in vivo experimental models (data not published).

**LEPTIN-RECEPTOR-BLOCKING ANTIBODIES**

Leptin binding and signaling could be prevented by using high-affinity monoclonal antibodies that act as antagonists by interacting with the leptin receptor (74–76). A leptin-receptor-specific antibody has been tested in an in vitro study, and resulted in a reduction of both leptin signaling and leptin’s capability to activate monocytes and induce proliferation of peripheral blood mononuclear cells (75). The use of polyclonal antibodies that block leptin has also been proposed (74, 76). However, such antibodies could increase, rather than block, the activity of leptin in vivo, by prolonging its half-life in the circulation. The leptin-antibody complex would be larger than leptin alone, thereby decreasing kidney-mediated clearance of leptin (71). An alternative approach is represented by single-domain antibodies, i.e., small, monomeric antibody fragments of around 15 kDa that contain a single antigen-binding domain. These fragments are able to target the leptin receptor and block the ligand-induced conformational switch without interfering with leptin–leptin receptor interactions. They can bind to the leptin receptor with high affinity and do not cross the blood–brain barrier; thereby, they could selectively inhibit the peripheral activity of leptin (71).

**CONCLUSION**

Adipokine leptin, produced by adipocytes, fibroblasts, and breast cancer cells, may act in an endocrine, paracrine as well as autocrine manner on breast cancer tissue (Figure 1). Activation of leptin-signaling results in concurrent activation of multiple oncogenic pathways leading to increased proliferation, acquisition of mesenchymal phenotype, enhanced migration, and invasion of tumor cells. Knowledge of the complex biological molecular network of leptin-signaling responsible for mammary carcinogenesis within tumor microenvironment provides a strong rationale for developing new agents, tailored to target the leptin and its receptor pathways, for therapeutic intervention in breast cancer treatment, particularly in women with obesity.

**ACKNOWLEDGMENTS**

This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC) grant IG11595.
REFERENCES

1. Arendt LM, Rudnick JA, Keller PJ, Kuperwasser C. Stroma in breast development and disease. 
Semin Cell Dev Biol (2009) 21:11–8. doi:10.1016/j.secdb.2009.10.003.

2. Abouessekra A. Role of cancer-associated fibroblasts in breast cancer development and 
progression. *Int J Dev Biol* (2011) 55:841–9. doi:10.1387/ijdb.113362a2.

3. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progress. 
*Nature* (2004) 432:332–7. doi:10.1038/nature03096.

4. Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Penault-Llorca F, Guillot J, 
Argiles JM. Leptin expression in colorectal and breast cancer patients. 
*Biochem Biophys Res Commun* (2002) 293:622–8. doi:10.1006/bbrc.2001.2005-X.

5. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR. Serum immunoreactive-leptin concentrations in normal-weight and obese 
human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. 
*Nat Med* (1995) 1:1155–61. doi:10.1038/nm1155.

6. Maffei M, Halas J, Ravussin E, Pratley RE, Lee GH, Zhang Y. Leptin levels in weight-reduced subjects. 
*Nature* (1994) 365:585–9.

7. Arendt LM, Rudnick JA, Keller PJ, Kuperwasser C. Stroma in breast development and disease. 
*Semin Cell Dev Biol* (2009) 21:11–8. doi:10.1016/j.secdb.2009.10.003.

8. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, 
Giuodicelli Y. Leptin mediates a proliferative response in human MCF7 breast 
cancer cells. *Int J Cancer Lett* (2011) 6:236–73. doi:10.1016/j.ijc.2011.07.002.

9. Ahima RS, Osei SY. Leptin signaling. *Physiol Behav* (2004) 81:223–41. doi:10. 
1016/j.physbeh.2004.02.014.

10. Sweeney G. Leptin signalling. *Cell Signal* (2002) 14:653–65. doi:10.1016/s0898-6568(02)00086-2.

11. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. 
*Clin Cancer Res* (2004) 10:4325–31. doi:10.1158/1078-0432.CCR-03-0749.

12. Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, Shimomura I. High 
expression of leptin receptor mRNA in breast cancer tissue predicts poor 
egress for patients with high, but not low, serum leptin levels. 
*Int J Cancer* (2006) 118:1414–9. doi:10.1002/jic.21543.

13. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML. Leptin 
enhances, via AP-1, expression of aromatase in the MCF-7 cell line. 
*J Biol Chem* (2003) 278:26868–76. doi:10.1074/jbc.M301695200.

14. Catalano S, Mauro L, Bonofgio D, Pellegrino M, Qi H, Rizza P. In vivo and in vitro evidence that PPARgamma ligands are antagonists of leptin signaling in breast cancer. 
*Am J Pathol* (2011) 179:1030–40. doi:10.1016/j.ajpath.2011.04.026.

15. Dieudonne MN, Machinal-Quelin F, Serazin-Lery V, Leneveu MC, Pequerry R, 
Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast 
cancer cells. *Biochem Biophys Res Commun* (2002) 293:622–8. doi:10.1006/bbrc.2001.2005-X.

16. Garofalo C, Sisci D, Surmacz E. Leptin interferes with the effects of the antiestro- 
rogen ICI 182,780 in MCF-7 breast cancer cells. 
*Clin Cancer Res* (2004) 10:1414–9. doi:10.1158/1078-0432.CCR-03-0749.

17. Garofalo C, Sisci D, Surmacz E. Leptin interferes with the effects of the antiestro- 
gen ICI 182,780 in MCF-7 breast cancer cells. 
*Clin Cancer Res* (2004) 10:1414–9. doi:10.1158/1078-0432.CCR-03-0749.

18. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J. Identification of leptin 
receptor (OB-R) in human breast cancer. *Cancer Res* (2004) 64:5870–5. doi:10.1158/0008-5472.CAN-04-0655.

19. Giordano C, Vizza D, Panza S, Barone I, Bonofgio D, Lanzino M. Leptin 
increases HER2 protein levels through a STAT3-mediated up-regulation of 
Hsp90 in breast cancer cells. *Mol Oncol* (2011) 5:397–91. doi:10.1016/j.molonc.2011.12.002.

20. Ray A, Nkhata KJ, Cleary MP. Effects of leptin on human breast cancer cell 
in vitro. *J Surg Res* (2003) 113:50–5. doi:10.1002/jrs.480-03 
0166-5.

21. Yu W, Gu JC, Liu JZ, Wang SH, Wang Y, Zhang ZT. Regulation of estrogen 
receptor alpha and beta in human breast carcinoma by exogenous leptin 
and investigation of breast tumor microenvironment crosstalk.
Andò et al. Leptin and breast tumor microenvironment crosstalk

Frontiers in Oncology | Molecular and Cellular Oncology

in nude mouse xenograft model. Chin Med J (Eng) (2010) 123:337–43. doi:10.3760/cma.journ.0336-6999.2010.03.015

43. Yom CK, Lee KM, Han W, Kim SW, Kim HS, Moon BI. Leptin as a potential target for estrogen receptor-positive breast cancer. J Breast Cancer (2013) 16:138–45. doi:10.4048/jbcs.2013.16.2.138

44. Magoffin DA, Weitsman SR, Agarwal SK, Jakimiuk AJ. Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women. Genikol Pol (1999) 70:1–7.

45. Bronowicki KA, McMlnnes KJ, Hunger NI, Oakhill JS, Steinberg GR, Simpson ER. Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Res (2009) 69:5392–9. doi:10.1158/0008-5472.CAN-09-0108

46. Schaffler A, Scholmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer – endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab (2007) 3:345–54. doi:10.1038/ncepmet00456

47. De Weaver O, Marel M. Role of tissue stroma in cancer cell invasion. J Pathol (2003) 200:429–47. doi:10.1002/path.1398

48. Guo MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci (2010) 123:3507–14. doi:10.1242/jcs.072900

49. Lebret SC, Newgreen DF, Thompson EW, Ackland ML. Induction of epithelial to mesenchymal transition in PMCA42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res (2007) R9:19. doi:10.1186/bcr1656

50. Yu X, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer (2014) 110:724–32. doi:10.1038/bjc.2013.768

51. Yan D, Artanani D, Saxena NK, Sharma D. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires beta-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Mammary Gland Biol Neoplasia (2013) 18:369–80. doi:10.1007/s10911-013-9308-2

52. Gao S, Liu M, Wang G, Tornoralla-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 287:8598–612. doi:10.1016/j.bjba.2011.11.32800

53. Mallip P, Leonnard T, Kirby J, Messon A. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev (2014) 40:541–6. doi:10.1016/j.ctrv.2013.10.006

54. Guo S, Liu M, Wang G, Tornoralla-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 1825:207–22. doi:10.1016/j.bjba.2012.01.002

55. Saxena NK, Sharma D. Multiaxepedent leptin network: the molecular connection of non-pegylated and pegylated superactive ovine leptin antagonists. Protein Expr Purif (2006) 47:128–36. doi:10.1016/j.pep.2005.09.016

56. Gertler A. Development of leptin antagonists and their potential use in experimental biology and medicine. Trends Endocrinol Metab (2006) 17:372–8. doi:10.1016/j.tem.2006.09.006

57. Salomon G, Niv-Spector L, Gussakovskiy EE, Gertler A. Large-scale preparation of biologically active mouse and rat leptins and their L93A/D340/A41A mutants which act as potent antagonists. Protein Expr Purif (2006) 47:128–36. doi:10.1016/j.pep.2005.09.016

58. Niv-Spector L, Raver N, Friedman-Einatz M, Grossclaude J, Gussakovskiy EE, Livnah O. Mapping leptin-interacting sites in recombinant leptin-binding domain (LBD) cheloned from chicken leptin receptor. Biochem J (2005) 390:475–84. doi:10.1042/BJ200505233

59. Gussakovskiy EE, Gertler A. Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonists. Protein Expr Purif (2006) 47:128–36. doi:10.1016/j.pep.2005.09.016

60. Gertler A. Development of leptin antagonists and their potential use in experimental biology and medicine. Trends Endocrinol Metab (2006) 17:372–8. doi:10.1016/j.tem.2006.09.006

61. Niv-Spector L, Shpilman M, Boisclair Y, Gertler A. Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonists. Protein Expr Purif (2006) 47:128–36. doi:10.1016/j.pep.2005.09.016

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 23 September 2014; paper pending published: 27 October 2014; accepted: 12 November 2014; published online: 26 November 2014.

Copyright © 2014 Andò, Barone, Giordano, Bonofiglio and Catalano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided that the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.